Indegra Therapeutics is uniquely positioned to build a multi-modal integrin platform, to enable the discovery of new and effective treatments with significant therapeutic and commercial benefits.
Integrin modulators as therapeutics represent a huge, but largely untapped reservoir, for patient and commercial benefit, with a druggable target class of 24 extracellular signalling proteins.
There is a great demand for successful intern treatments. With many years of pharma drug discovery experience, and world-class medicinal chemistry know-how, the team is perfectly positioned to overcome previous clinical failures seen in the development of integrin inhibitor drugs. Their experience and wide network in the integrin field, will enable a robust route to the clinic.